The $350M dilutive offering follows positive Phase 3 data but signals management's need for capital ahead of a binary NDA decision (mid-2027). Monitor the final pricing and the number of shares sold; the 45-day lock-up expiration could add selling pressure. The extended cash runway into 2030 reduces near-term financing risk but at the cost of significant shareholder dilution.
Price Chart
Executive Summary
Disc Medicine is filing a preliminary prospectus supplement for a $350M underwritten public offering of common stock and pre-funded warrants, following positive Phase 3 APOLLO topline results for bitopertin in EPP/XLP announced on October 19, 2026. The offering will significantly dilute existing shareholders (immediate dilution of $ per share, with net tangible book value of $16.80/share pre-offering), but extends the company's cash runway into 2030 (from 2029 without the offering) and funds NDA resubmission and potential commercialization of bitopertin.
Key Facts
- Offering size: $350,000,000 of common stock and pre-funded warrants.
- Underwriters have a 30-day option to purchase up to an additional $52,500,000 of common stock.
- Closing price on October 19, 2026: $78.93 per share.
- Net tangible book value as of June 30, 2026: $644.2 million, or $16.80 per share.
- Preliminary cash, cash equivalents and marketable securities as of September 30, 2026: approximately $682.8 million.
- Net proceeds estimated at approximately $328 million, extending cash runway into 2030 (from 2029 without the offering).
- Positive Phase 3 APOLLO topline results announced October 19, 2026: both co-primary endpoints met (PPIX reduction -41.4% vs placebo, p<0.0001; time in light without pain +12.2 hours vs placebo, p=0.0010).
- Company plans to resubmit NDA for bitopertin by end of 2026, with FDA decision anticipated by mid-2027.
- Lock-up agreements for directors and executive officers: 45 days following the offering.
- Pre-funded warrants have an exercise price of $0.0001 per share and do not expire.
Financial Impact
Immediate and substantial dilution to existing shareholders; net tangible book value per share of $16.80 pre-offering will be diluted by the offering price per share (undisclosed). Proceeds extend cash runway from 2029 to 2030.
Risk Factors
- Immediate and substantial dilution to existing shareholders.
- Potential for further dilution from exercise of pre-funded warrants, stock options, and RSUs.
- Risk that the NDA resubmission for bitopertin may not be approved by mid-2027, or may face additional delays.
- Sales of a substantial number of shares after the lock-up period (45 days) could depress the stock price.
- The company has broad discretion over use of proceeds, which may not align with shareholder interests.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-425425 |
| Document: 0001193125-26-425425-index-headers.html | 0001193125-26-425425 |
| Document: 0001193125-26-425425-index.html | 0001193125-26-425425 |
| Document: 0001193125-26-425425.txt | 0001193125-26-425425 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $74.95 | awaiting T+20 | — | $76.90 (−2.60%) |
Oct 21, 2026 4d ago | 424B5 | $75.03 | awaiting T+20 | — | $76.90 (−2.49%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $76.90 (+2.49%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $76.90 (+2.49%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $76.90 (+2.49%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $76.90 (+1.18%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $76.90 (+1.18%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $76.90 (+1.18%) |
Oct 19, 2026 6d ago | 424B5 | $79.48 | awaiting T+20 | — | $76.90 (+3.25%) |
Oct 19, 2026 6d ago | 144 | $79.48 | awaiting T+20 | — | $76.90 (−3.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers